Quarterly report [Sections 13 or 15(d)]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

v3.25.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
 3 Months Ended
Mar. 31, 2025
Accounting Policies [Abstract]  
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
The following is a summary of awards outstanding as of March 31, 2025 and 2024, which are not included in the computation of basic and diluted weighted average shares:
Three months ended
March 31,
2025 2024
Stock options (excluding exercisable penny stock options) 7,036,576  5,884,608 
Restricted stock units 283,411  217,881 
Warrants 5,827,031  5,152,397 
Total 13,147,018  11,254,886 
Schedule of Segment Reporting Information, by Segment In addition to the significant expense categories included within the total net loss presented on the Company's Statements of Operations, the following table sets forth significant segment expenses:
(in thousands) Three months ended March 31,
2025 2024
Employee expenses $ 3,039  $ 2,559 
Research and Development (excluding employee expenses):
Consulting and professional fees 415  649 
Clinical study expenses 5  241 
Product development 709  195 
Other* 304  281 
Total Research and development expense $ 1,433  $ 1,366 
General and administrative expense (excluding employee expenses):
General and administrative expenses 735  774 
Commercialization readiness expenses 297  85 
Total General and administrative expense 1,032  859 
Total operating expenses $ 5,504  $ 4,784 

* Other primarily includes patent and testing expenses for three months ended March 31, 2025 and 2024.